Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept + ESA in LR-MDS Without RS
NCT05181735Phase 2Recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- May 2022
- Primary completion
- Dec 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started May 2022; status: recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05181735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181735.